What is the recommended management of an acute gout flare and subsequent urate‑lowering therapy, including options for patients with renal or gastrointestinal contraindications?

Gouty Arthritis Treatment

Acute Gout Flare Management

For an acute gout attack, initiate therapy within 24 hours using NSAIDs, colchicine, or corticosteroids as first-line options, selecting the agent based on renal function, cardiovascular risk, gastrointestinal comorbidities, and drug interactions. 1, 2

Treatment Selection Algorithm

Step 1: Assess renal function

• If eGFR < 30 mL/min (severe renal impairment): Use oral prednisone 30–35 mg daily for 5 days; both NSAIDs and colchicine are contraindicated due to risk of acute kidney injury and fatal toxicity. 1, 2, 3
• If eGFR 30–59 mL/min (moderate impairment): Prefer corticosteroids; NSAIDs carry high risk of acute kidney injury, colchicine requires dose reduction to 0.6 mg once daily. 2
• If eGFR ≥ 60 mL/min: All three options are appropriate; proceed to Step 2. 2

Step 2: Check for drug interactions (colchicine contraindications)

• If patient is taking strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil) AND has any degree of renal or hepatic impairment: Colchicine is absolutely contraindicated due to risk of fatal toxicity; choose NSAIDs or corticosteroids. 1, 2

Step 3: Assess cardiovascular and gastrointestinal risk

• If heart failure, established cardiovascular disease, active/recent peptic ulcer disease, cirrhosis, or on anticoagulation: Avoid NSAIDs; use colchicine (if no contraindications) or corticosteroids. 1, 2, 3

Step 4: Consider timing from symptom onset

• If ≤ 36 hours from onset: Colchicine is most effective when started within 12 hours; efficacy declines sharply after 36 hours. 1, 2
• If > 36 hours from onset: Do not use colchicine; select NSAIDs or corticosteroids. 1, 2

Step 5: Assess joint involvement

• For 1–2 large, accessible joints (knee, ankle): Consider intra-articular corticosteroid injection (triamcinolone 40 mg for knee, 20–30 mg for ankle) as an alternative to systemic therapy. 1, 2, 3
• For ≥ 4 joints or multiple large joints (polyarticular): Initiate combination therapy (colchicine + NSAID, oral corticosteroid + colchicine, or intra-articular steroid + any oral agent); avoid combining systemic NSAID with systemic corticosteroid due to synergistic gastrointestinal toxicity. 2

Specific Dosing Regimens

Colchicine (low-dose regimen)

• Loading dose: 1.2 mg orally at first sign of flare, followed 1 hour later by 0.6 mg (total 1.8 mg over 1 hour). 1, 2
• Maintenance: After 12-hour pause, resume 0.6 mg once or twice daily until attack resolves. 1, 2
• This regimen achieves ≥ 50% pain reduction (NNT = 3–5) with significantly fewer gastrointestinal adverse effects (23% diarrhea) compared to obsolete high-dose regimens (77% diarrhea). 2
• Absolute contraindications: Severe renal impairment (CrCl < 30 mL/min), concurrent strong CYP3A4/P-gp inhibitors with any renal/hepatic impairment. 1, 2

NSAIDs (full anti-inflammatory doses)

• Naproxen 500 mg twice daily, indomethacin 50 mg three times daily, or sulindac 200 mg twice daily; continue at full dose throughout entire attack until complete resolution—do not taper early. 1, 2
• No single NSAID has demonstrated superior efficacy; indomethacin is not more effective than naproxen or ibuprofen despite common perception. 1
• Contraindications: Severe renal impairment (eGFR < 30 mL/min), heart failure, cirrhosis, active peptic ulcer disease, anticoagulation therapy. 1, 2

Corticosteroids

• Oral prednisone: 0.5 mg/kg/day (approximately 30–35 mg) for 5–10 days at full dose then stop abruptly, OR 2–5 days at full dose followed by 7–10 day taper. 1, 2, 3
• Level A evidence shows oral corticosteroids are equally effective as NSAIDs but with fewer adverse events (27% vs 63%). 2, 3
• Intramuscular: Triamcinolone acetonide 60 mg single injection for patients unable to take oral medications. 2, 3
• Intravenous: Methylprednisolone 0.5–2.0 mg/kg (40–140 mg) for NPO patients; repeat as clinically indicated. 2, 3
• Contraindications: Active systemic fungal infection (absolute), current active infection (relative). 2, 3

Critical Timing Considerations

• Maximum therapeutic benefit occurs when treatment is initiated within 12–24 hours of symptom onset; delays beyond 24 hours markedly reduce effectiveness of all agents. 2
• Colchicine should not be started after 36 hours from symptom onset as efficacy drops dramatically. 1, 2

---

Urate-Lowering Therapy (ULT)

Do not initiate urate-lowering therapy during an acute gout flare; wait until the attack has completely resolved. 1, 2

If the patient is already on allopurinol or febuxostat, continue the medication without interruption during the acute flare. 1, 2

Indications to Initiate ULT

Strong indications (initiate after first flare):

• Subcutaneous tophi 1, 2
• Radiographic joint damage attributable to gout 1, 2
• Chronic kidney disease stage ≥ 3 1, 2

Conditional indications:

• ≥ 2 gout attacks per year (recurrent gout) 1
• Serum urate > 9 mg/dL 1
• Patient preference for early intervention 1
• Young age at disease onset 1
• Urolithiasis 1

Avoid initiating ULT after a first gout attack or in patients with infrequent attacks (< 2 per year) unless high-risk features are present. 1

Allopurinol Initiation and Titration

Start allopurinol at 100 mg daily (or 50 mg daily if CrCl 30–50 mL/min) and increase by 100 mg every 2–4 weeks until serum urate falls below 6 mg/dL. 1, 2, 4

• Typical maintenance dose: 300–600 mg daily; maximum 800 mg daily. 2, 4
• Starting at a high dose (e.g., 300 mg daily) significantly increases the risk of acute flares and allopurinol hypersensitivity syndrome; low-dose initiation is essential. 2, 4
• Allopurinol may be titrated above 300 mg even with renal impairment, provided patients receive education and monitoring for toxicity (pruritus, rash, transaminase elevation). 2
• Renal dosing: With CrCl 10–20 mL/min, use 200 mg daily; with CrCl < 10 mL/min, do not exceed 100 mg daily. 4

Serum Urate Targets

• Standard target: < 6 mg/dL (360 µmol/L) for all gout patients, maintained lifelong. 1, 2
• Aggressive target: < 5 mg/dL (300 µmol/L) for severe gout (tophi, chronic arthropathy, frequent attacks) until crystal dissolution. 2
• Avoid maintaining serum urate < 3 mg/dL long-term. 2

Alternative ULT Agents

Febuxostat

• Indicated when allopurinol at an appropriate dose fails to achieve target urate or when allopurinol is intolerable. 1, 2
• Start 40 mg daily and titrate to 80 mg (or 120 mg if needed) to achieve serum urate < 6 mg/dL. 2
• Febuxostat and allopurinol (40 mg/day vs 300 mg/day) are equally effective at decreasing serum urate levels. 1
• Does not require renal dose adjustment in mild-to-moderate chronic kidney disease. 2

Uricosuric agents (probenecid, benzbromarone, sulphinpyrazone)

• Appropriate for patients with normal renal function; relatively contraindicated in those with urolithiasis. 1
• Benzbromarone can be used in patients with mild-to-moderate renal insufficiency but carries a small risk of hepatotoxicity. 1

Pegloticase

• Reserved for crystal-proven, severe, debilitating chronic tophaceous gout when all other therapies at maximal doses fail to reach serum urate target. 2, 5
• Monitor serum uric acid levels prior to infusions; consider discontinuing if levels increase above 6 mg/dL. 5

---

Prophylaxis During ULT Initiation

Prescribe colchicine 0.6 mg once or twice daily for at least 6 months when starting or adjusting allopurinol or febuxostat to prevent acute gout flares. 1, 2

• Duration: Continue for 3 months after achieving target serum urate < 6 mg/dL if no tophi are present; continue for 6 months after reaching target if tophi are present. 1, 2
• High-quality evidence shows colchicine prophylaxis reduces the proportion of patients experiencing flares from 77% to 33% during allopurinol initiation. 2
• Stopping prophylaxis at 8 weeks leads to a doubling of flare rates (from 20% to 40%). 2

Alternative prophylaxis (if colchicine contraindicated):

• Low-dose NSAID plus proton-pump inhibitor (e.g., naproxen 250 mg twice daily with omeprazole 20 mg daily). 2, 6
• Low-dose prednisone (< 10 mg/day) as second-line option; avoid high-dose prednisone (> 10 mg/day) for prophylaxis. 2, 3

Renal impairment dose adjustments for prophylaxis:

• Mild-to-moderate impairment (CrCl 30–80 mL/min): Reduce colchicine to 0.6 mg once daily. 2
• Severe impairment (CrCl < 30 mL/min): Start colchicine at 0.3 mg once daily with close monitoring, or avoid entirely and use alternative prophylaxis. 2

---

Lifestyle and Non-Pharmacologic Measures

• Weight loss and regular physical activity lower excess mortality associated with hyperuricemia. 2
• Dietary recommendations: Limit alcohol (especially beer and spirits), sugar-sweetened beverages, fructose-rich foods, large meals, and excessive meat/seafood; encourage low-fat dairy, coffee, and cherries. 1, 2
• Medication review: Replace loop or thiazide diuretics when possible; consider losartan or calcium-channel blockers for hypertension; use statins or fenofibrate for hyperlipidemia. 1, 2
• Topical ice applied to the affected joint is conditionally recommended as an adjunctive measure to reduce pain and swelling. 2

---

Common Pitfalls to Avoid

• Do not delay acute treatment beyond 24 hours; effectiveness declines sharply. 2
• Do not start colchicine after 36 hours from symptom onset; efficacy drops dramatically. 1, 2
• Do not taper NSAIDs early; maintain full dose throughout the attack. 1, 2
• Do not initiate allopurinol at 300 mg daily; starting at a high dose increases risk of flares and hypersensitivity syndrome. 2, 4
• Do not stop ULT during an acute flare if the patient is already on therapy. 1, 2
• Do not omit colchicine prophylaxis when starting ULT; flare rates roughly double without it. 2
• Do not combine colchicine with strong CYP3A4/P-gp inhibitors in patients with any renal or hepatic impairment due to fatal toxicity risk. 1, 2
• Do not use obsolete high-dose colchicine regimens (e.g., 0.5 mg every 2 hours); they cause severe diarrhea without added benefit. 1, 2
• Do not combine systemic NSAID with systemic corticosteroid due to synergistic gastrointestinal toxicity. 2